Last checked at 21 Oct 2014 11:19
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Immupharma Share News (IMM)
IMM Share
Price
IMM Share
News
IMM Share
Chat
IMM Share
Trades12
IMM
Live RNS
IMM Share
Charts
IMM Level 2
Console
IMM Live
Share Price
IMM Broker
Ratings
IMM Directors
Deals
IMM Financial
Diary
IMM
Fundamentals
IMM Short
Positions
IMM
Media
Immupharma Information
Share Price Information for Immupharma (IMM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.15
Bid:
2.10
Ask:
2.19
Change:
0.035 (1.66%)
Spread:
0.09 (4.286%)
Open:
2.06
High:
2.15
Low:
2.06
Prev. Close:
2.11
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Immupharma raises ?2.66m from subscription agreement with institutional investor
Wed, 26th Jun 2019 11:15
(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.Immupharma revealed Lanstead will subscribe for 26.56m new ordinary shares at an issue price of 10p each, representing approximately 19% of the company's existing issued share capital, at a 26.5% discount to the closing mid-market price of the group's shares on Tuesday.The AIM-listed firm told shareholders that the subscription, which was the maximum possible amount under Lanstead's existing authorisation, marked a further supportive investment in the company by Lanstead, following the £4.43m it poured into the group back in February 2016.Immupharma also inked a sharing agreement with Lanstead, which entitled the company to recoup the proceeds on a pro rata monthly basis over a period of 24 months, allowing the company to benefit from positive future share price performance, and agreed to issue another 1.32m ordinary shares to Lanstead in connection with it.The group intends to use the funds to cover the execution of its corporate strategy.Chairman Tim McCarthy said: "Lanstead has been very supportive of the company since their first investment in 2016 and this latest subscription demonstrates their continued support and the alignment of both the company and Lanstead's belief of the potential of substantial value enhancement for shareholders in the future execution of the company's recently stated corporate strategy."As of 1115 BST, Immupharma shares sank 16.76% to 11.32p.
More News
21 Oct 2014 11:16
Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial
Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per
Read more21 Oct 2014 11:00
5 Oct 2014 13:32
Sunday share tips: BG Group, Genel Energy, Palace Capital
Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I
Read more16 Jun 2014 10:52
ImmuPharma Granted New US Patent For Nucant Cancer Treatments
LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate
Read more16 Jun 2014 08:14
Immupharma gains new patents for Nucant treatments
Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane
Read more21 May 2014 13:14
ImmuPharma's patient approach disappoints
Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t
Read more21 May 2014 11:45
ImmuPharma Losses Widen As It Accelerates Research And Development
LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million
Read more27 Sep 2013 12:23
27 Sep 2013 10:30
ImmuPharma reports half-year loss
ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it
Read more13 Aug 2013 09:17
Immupharma progresses with cancer treatment trials
ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p
Read more28 Jan 2013 16:06
ImmuPharma non-exec reduces stake
Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific
Read more